In a patient with acute bacterial sinusitis who has received amoxicillin‑clavulanate (875 mg/125 mg orally twice daily) for 48–72 hours without clinical improvement, what is the appropriate next step in management?

Management of Acute Bacterial Sinusitis After Augmentin Failure

Switch to a Respiratory Fluoroquinolone Immediately

For a patient with acute bacterial sinusitis who has failed 48–72 hours of amoxicillin-clavulanate (Augmentin) 875 mg/125 mg twice daily, switch immediately to levofloxacin 500 mg once daily for 10–14 days or moxifloxacin 400 mg once daily for 10 days. 1, 2, 3 These respiratory fluoroquinolones provide 90–92% predicted clinical efficacy against drug-resistant Streptococcus pneumoniae (including multidrug-resistant strains) and β-lactamase-producing Haemophilus influenzae and Moraxella catarrhalis—the organisms most likely responsible for treatment failure. 1, 2, 3

---

Why Augmentin Failed: Understanding the Microbiology

The failure of amoxicillin-clavulanate after 48–72 hours suggests one of three scenarios: 1, 2

• Drug-resistant S. pneumoniae (DRSP) with high-level penicillin resistance that even the clavulanate component cannot overcome 1, 2
• β-lactamase-producing H. influenzae or M. catarrhalis in quantities exceeding the inhibitory capacity of 125 mg clavulanate 1, 2
• Misdiagnosis—the patient may not have bacterial sinusitis at all, but rather viral rhinosinusitis, fungal infection, or an anatomic obstruction 1, 2

The IDSA guideline explicitly states that an alternative management strategy is recommended if symptoms worsen after 48–72 hours or fail to improve despite 3–5 days of initial empiric antimicrobial therapy. 1 This patient meets failure criteria at 48–72 hours. 1

---

First-Line Second-Line Therapy: Respiratory Fluoroquinolones

Levofloxacin Regimen

• Levofloxacin 500 mg orally once daily for 10–14 days (or until symptom-free for 7 consecutive days, typically 10–14 days total) 2, 3
• Provides 90–92% predicted clinical efficacy against all three major sinusitis pathogens 2, 3
• Achieves 100% microbiologic eradication of S. pneumoniae in clinical trials 2
• Covers multidrug-resistant S. pneumoniae (MDRSP) that fails amoxicillin-clavulanate 2, 3

Moxifloxacin Regimen

• Moxifloxacin 400 mg orally once daily for 10 days 2, 3
• Equivalent 90–92% predicted efficacy 2, 3
• Once-daily dosing may improve compliance 2

---

Alternative Second-Line Option: High-Dose Amoxicillin-Clavulanate

If fluoroquinolones are contraindicated (pregnancy, tendon disorder, QT-prolongation risk, or patient refusal), escalate to high-dose amoxicillin-clavulanate 2 g/125 mg twice daily for 10–14 days. 2, 4 This regimen doubles the amoxicillin dose to overcome intermediate-level penicillin resistance in S. pneumoniae. 2, 4

However, a 2021 randomized trial found no clinical benefit of high-dose over standard-dose amoxicillin-clavulanate in adults with acute sinusitis (44.3% vs. 36.4% improvement at day 3, difference −7.9%, 95% CI −24.4% to 8.5%, P=0.35), and diarrhea rates were identical (40.8% vs. 43.1%). 5 This evidence suggests that if standard-dose Augmentin failed, high-dose Augmentin is unlikely to succeed—making fluoroquinolones the superior choice. 5

---

Third-Generation Cephalosporins: Inferior but Acceptable

If both fluoroquinolones and high-dose amoxicillin-clavulanate are contraindicated, consider: 2, 3

• Cefpodoxime proxetil 200 mg twice daily for 10 days—superior H. influenzae activity compared to second-generation cephalosporins 2, 3
• Cefdinir 300 mg twice daily for 10 days 2, 3

These agents have limitations against drug-resistant S. pneumoniae and should be reserved for patients who cannot take fluoroquinolones or β-lactams. 2, 3

---

Do NOT Use These Antibiotics

Azithromycin and Macrolides

Never use azithromycin or clarithromycin for sinusitis treatment failure. 1, 2 Resistance rates exceed 20–25% for both S. pneumoniae and H. influenzae, making macrolides unsuitable for empiric therapy. 1, 2 The American Academy of Pediatrics explicitly contraindicates azithromycin for acute bacterial sinusitis due to resistance patterns. 2

Trimethoprim-Sulfamethoxazole (Bactrim)

Avoid trimethoprim-sulfamethoxazole due to 50% resistance in S. pneumoniae and 27% resistance in H. influenzae. 2, 3

Doxycycline

Doxycycline 100 mg once daily for 10 days is an acceptable but suboptimal alternative with only 77–81% predicted efficacy and a 20–25% bacteriologic failure rate due to limited H. influenzae coverage. 2, 3 Reserve doxycycline only when fluoroquinolones are contraindicated and cephalosporins cannot be used. 2, 3

---

Essential Adjunctive Therapies (Add to All Patients)

Intranasal Corticosteroids (Strong Evidence)

Prescribe intranasal corticosteroids (mometasone, fluticasone, or budesonide) twice daily to reduce mucosal inflammation and accelerate symptom resolution. 1, 2 This recommendation is supported by strong evidence from multiple randomized controlled trials. 1, 2

Saline Nasal Irrigation

Recommend saline nasal irrigation 2–3 times daily for symptomatic relief and mucus clearance. 1, 2

Analgesics

Prescribe acetaminophen or ibuprofen for pain and fever control. 1, 2

---

Reassessment Protocol: When to Escalate Further

Day 3–5 After Switching Antibiotics

Reevaluate clinical response 3–5 days after starting the fluoroquinolone. 1, 2 If there is no improvement (persistent purulent drainage, unchanged facial pain, or worsening), this indicates treatment failure and warrants: 1, 2

• Immediate ENT referral for consideration of sinus aspiration cultures 1
• CT imaging to exclude complications (orbital cellulitis, meningitis, intracranial abscess) or alternative diagnoses (fungal sinusitis, anatomic obstruction) 1, 2

Day 7 Reassessment

By day 7 of the new antibiotic regimen, the majority of patients should demonstrate significant improvement. 2 Persistent or worsening symptoms at this point should prompt: 1, 2

• Confirmation of diagnosis—consider fungal sinusitis, chronic rhinosinusitis, or anatomic obstruction 1, 2
• Exclusion of complications—orbital cellulitis, meningitis, brain abscess 1, 2
• ENT referral for endoscopic evaluation and possible sinus aspiration cultures 1

---

When to Obtain Sinus Cultures

The IDSA guideline recommends that cultures be obtained by direct sinus aspiration (not nasopharyngeal swab) in patients who have failed to respond to empiric antimicrobial therapy. 1 Endoscopically guided cultures of the middle meatus may be considered as an alternative in adults, but nasopharyngeal cultures are unreliable and not recommended. 1

Obtain sinus cultures if: 1

• No improvement after 7 days of appropriate second-line fluoroquinolone therapy 1
• Worsening symptoms at any time during treatment 1
• Suspected complications (orbital cellulitis, meningitis, intracranial abscess) 1
• Immunocompromised state (HIV, diabetes, chronic corticosteroid use) 1

---

Red Flags: When to Refer to ENT Immediately

Refer urgently to otolaryngology if any of the following occur: 1, 2

• No clinical improvement after 7 days of appropriate second-line fluoroquinolone therapy 1, 2
• Worsening symptoms at any point (increasing facial pain, fever, purulent drainage) 1, 2
• Signs of complications: severe headache, visual changes, periorbital swelling/erythema, proptosis, diplopia, altered mental status, cranial nerve deficits 1, 2
• Recurrent sinusitis (≥3 episodes per year) requiring evaluation for underlying allergic rhinitis, immunodeficiency, or anatomic abnormalities 1, 2

---

Expected Timeline for Symptom Improvement

• Noticeable improvement should occur within 3–5 days of starting the fluoroquinolone 2
• Complete symptom resolution typically occurs by 10–14 days or when the patient is symptom-free for 7 consecutive days 2
• Only 30–41% of patients achieve improvement by days 3–5—zero improvement at this stage indicates likely treatment failure 2

---

Critical Pitfalls to Avoid

Do Not Continue Ineffective Therapy

Waiting beyond 3–5 days to change therapy in non-responders delays effective treatment and may allow complications to develop. 1, 2 The IDSA guideline explicitly states that an alternative management strategy is recommended if symptoms fail to improve despite 3–5 days of initial empiric antimicrobial therapy. 1

Do Not Use Fluoroquinolones as First-Line Therapy

Fluoroquinolones should be reserved for second-line therapy or for patients with documented severe β-lactam allergies to prevent resistance development. 1, 2, 3 However, once Augmentin has failed, fluoroquinolones become the appropriate next step. 1, 2, 3

Ensure Adequate Treatment Duration

Continue the fluoroquinolone for a minimum of 10 days (or until symptom-free for 7 consecutive days, typically 10–14 days total) to prevent relapse. 2, 3 Shorter courses have been associated with higher recurrence rates. 2

Do Not Prescribe Antibiotics Based Solely on Purulent Discharge

Purulent nasal discharge alone does not indicate bacterial infection—it reflects neutrophilic inflammation common to viral disease. 2 However, this patient has already been on Augmentin for 48–72 hours without improvement, confirming bacterial sinusitis. 1, 2